Richard H. L. Natarajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard H. L. Natarajan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- James Robinson
Anthony Nolan Research Institute, Royal Free Hospital London UK
2 shared publications - Steven G. E. Marsh
UCL Cancer Institute London UK
2 shared publications - Andrew D. Yates
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus , Hinxton, CB10 1SD
1 shared publication - Dominic J. Barker
Anthony Nolan Research Institute Royal Free Hospital London UK
1 shared publication Michael A Cooper
Anthony Nolan Research Institute , London, NW3 2QG
1 shared publication- Neema P. Mayor
Anthony Nolan Research Institute, Royal Free Hospital London UK
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1152-D1158
The IPD-IMGT/HLA database: recent developments in sequence submission
The IPD-IMGT/HLA Database, https://www.ebi.ac.uk/ipd/imgt/hla/, contains >43 000 unique alleles from 47 genes recognized by the WHO Nomenclature Committee for Factors of the HLA System. The HLA system, located within the human major histocompatibility complex on chromosome 6, represents the most polymorphic genes in the human genome and is described as hyperpolymorphic. With the rapid growth of HLA sequencing worldwide, traditional approaches for submitting and accessing data have been challenged. To address these challenges, the IPD-IMGT/HLA Database has expanded its infrastructure by developing Application Programming Interfaces, enabling flexible queries via both a web-based interface and programmatic access. A major advancement is the launch of a new HLA Submission Tool, replacing the previous system after 26 years and >28 000 submissions. The updated tool provides a streamlined user experience, extensive data validation, and automated submissions through an application program interface (API). Importantly, it eliminates the burden of duplicate submissions by offering optional brokering to the European Nucleotide Archive on our submitters’ behalf, representing sequences in both databases while ensuring attribution. Together, the new submission tool, submission API, and ENA brokering reduce workload, increase efficiency, and provide ongoing support for the global HLA community.
- 18 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1152-D1158
Top Cited PapersOpen AccessThe IPD-IMGT/HLA database: recent developments in sequence submission
The IPD-IMGT/HLA Database, https://www.ebi.ac.uk/ipd/imgt/hla/, contains >43 000 unique alleles from 47 genes recognized by the WHO Nomenclature Committee for Factors of the HLA System. The HLA system, located within the human major histocompatibility complex on chromosome 6, represents the most polymorphic genes in the human genome and is described as hyperpolymorphic. With the rapid growth of HLA sequencing worldwide, traditional approaches for submitting and accessing data have been challenged. To address these challenges, the IPD-IMGT/HLA Database has expanded its infrastructure by developing Application Programming Interfaces, enabling flexible queries via both a web-based interface and programmatic access. A major advancement is the launch of a new HLA Submission Tool, replacing the previous system after 26 years and >28 000 submissions. The updated tool provides a streamlined user experience, extensive data validation, and automated submissions through an application program interface (API). Importantly, it eliminates the burden of duplicate submissions by offering optional brokering to the European Nucleotide Archive on our submitters’ behalf, representing sequences in both databases while ensuring attribution. Together, the new submission tool, submission API, and ENA brokering reduce workload, increase efficiency, and provide ongoing support for the global HLA community.